Oncolytics Biotech Files August 2024 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Aug 1, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Aug 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, 6-K, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed its August 2024 6-K, investors check for financial updates.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on August 1, 2024, reporting its financial results for the month of August 2024. The company, based in Calgary, Alberta, Canada, is a foreign private issuer and files under the 1934 Act.
Why It Matters
This filing provides an update on Oncolytics Biotech's financial status and reporting for the specified period, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- August 1, 2024 (date) — Filing Date
- Calgary, Alberta, Canada (location) — Company Headquarters
- 001-38512 (other) — SEC File Number
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer?
The filer is Oncolytics Biotech Inc.
When was this report filed?
The report was filed on August 1, 2024.
What is the company's principal executive office address?
The address is Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Does Oncolytics Biotech file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under Form 20-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-08-01 16:03:42
Filing Documents
- form6kq22024financialresul.htm (6-K) — 18KB
- oncyq22024financialresults.htm (EX-99.1) — 144KB
- 0001129928-24-000055.txt ( ) — 162KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date August 1, 2024 Kirk Look Chief Financial Officer